6-Substituted quinolines as ROR gamma t inverse agonists.
Barbay, J.K., Cummings, M.D., Abad, M., Castro, G., Kreutter, K.D., Kummer, D.A., Maharoof, U., Milligan, C., Nishimura, R., Pierce, J., Schalk-Hihi, C., Spurlino, J., Tanis, V.M., Urbanski, M., Venkatesan, H., Wang, A., Woods, C., Wolin, R., Xue, X., Edwards, J.P., Fourie, A.M., Leonard, K.(2017) Bioorg Med Chem Lett 27: 5277-5283
- PubMed: 29079472 
- DOI: https://doi.org/10.1016/j.bmcl.2017.10.027
- Primary Citation of Related Structures:  
5W4R, 5W4V - PubMed Abstract: 
We identified 6-substituted quinolines as modulators of the retinoic acid receptor-related orphan receptor gamma t (RORγt). The synthesis of this class of RORγt modulators is reported, and optimization of the substituents at the quinoline 6-position that produced compounds with high affinity for the receptor is detailed. This effort identified molecules that act as potent, full inverse agonists in a RORγt-driven cell-based reporter assay. The X-ray crystal structures of two full inverse agonists from this chemical series bound to the RORγt ligand binding domain are disclosed, and we highlight the interaction of a hydrogen-bond acceptor on the 6-position substituent of the inverse agonist with Glu379:NH as a conserved binding contact.
Organizational Affiliation: 
Discovery Immunology, Janssen Research and Development, LLC, Welsh and McKean Roads, Spring House, PA 19477, United States. Electronic address: kbarbay@its.jnj.com.